common
respiratori
virus
probabl
among
lead
caus
communityacquir
pneumonia
oddli
enough
long
underrecognis
patient
haematolog
malign
hm
perhap
part
due
lack
rapid
sensit
diagnost
method
effect
treatment
last
decad
expand
use
highdos
chemotherapi
haematopoiet
stem
cell
transplant
hsct
variou
malign
improv
prognosi
patient
hm
cost
increas
opportun
sever
infect
combin
develop
new
diagnost
method
introduct
antivir
drug
increas
infect
rate
rekindl
interest
effect
common
respiratori
virus
patient
hm
virus
recognis
true
opportunist
respiratori
pathogen
immunocompromis
host
clear
definit
common
respiratori
viru
virus
consist
produc
respiratori
manifest
consid
respiratori
virus
includ
member
follow
famili
rna
virus
orthomyxovirida
human
influenza
virus
paramyxovirida
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
human
metapneumovirus
mpv
coronavirida
human
respiratori
coronavirus
picornavirida
human
rhinovirus
virus
caus
respiratori
manifest
mani
patient
consid
respiratori
virus
often
associ
season
respiratori
event
exampl
includ
adenovirida
adenovirus
picornavirida
nonpoliomyelit
enterovirus
separ
chapter
book
focus
newli
discov
emerg
respiratori
virus
avian
influenza
virus
newli
discov
coronavirus
polyomavirus
ki
wu
human
bocaviru
mimiviru
cmv
herp
pneumonia
also
address
dr
chemali
colleagu
two
differ
chapter
book
human
influenza
virus
envelop
negativesens
singlestrand
rna
virus
classifi
three
antigen
type
b
c
envelop
influenza
b
virus
carri
two
major
antigen
protein
haemagglutinin
ha
neuraminidas
na
ha
allow
viru
bind
sialic
acidconjug
glycoprotein
surfac
respiratori
epithelium
cell
na
play
crucial
role
viral
dissemin
releas
newli
form
virion
host
cell
influenza
c
envelop
support
uniqu
protein
share
properti
ha
na
known
haemagglutininesterasefus
factor
influenza
b
c
virus
infect
human
mammalian
speci
wherea
influenza
also
infect
avian
speci
rsv
piv
type
envelop
negativesens
singlestrand
rna
virus
rsv
belong
paramyxoviru
genu
piv
pneumoviru
genu
paramyxovirida
famili
envelop
support
two
major
antigen
surfac
protein
one
bind
one
fusion
cell
membran
attach
host
cell
receptor
mediat
g
protein
rsv
haemagglutinin
neuraminidas
piv
fusion
protein
f
common
genera
allow
viru
penetr
within
host
cell
bind
antigen
variat
g
protein
determin
two
major
rsv
group
b
antigen
variat
also
occur
piv
less
immunolog
impact
natur
host
rsv
human
chimpanze
wherea
piv
infect
human
human
mpv
recent
discov
viru
belong
paramyxovirida
famili
human
mpv
genom
structur
similar
rsv
virus
display
surfac
protein
avail
data
indic
human
mpv
infect
human
although
viru
believ
origin
bird
human
rhinovirus
nonpoliomyelit
enterovirus
nonenvelop
singlestrand
rna
virus
belong
picornavirida
famili
rhinoviru
genu
consist
differ
serotyp
divid
three
speci
b
newli
describ
c
speci
base
antigen
variat
three
protein
found
capsid
surfac
enterovirus
divid
four
speci
b
c
share
structur
picornavirida
human
natur
host
virus
coronavirus
envelop
positivesens
singlestrand
rna
virus
belong
coronavirida
famili
envelop
support
two
main
protein
haemagglutininesteras
protein
antigen
protein
human
coronavirus
predomin
human
respiratori
coronaviru
strain
recent
identif
new
human
coronavirus
sar
adenovirus
nonenvelop
doublestrand
dna
virus
form
adenovirida
famili
six
subgenera
human
serotyp
adenovirus
describ
adenovirus
icosahedr
capsid
made
protein
subunit
call
capsomer
human
natur
host
virus
common
respiratori
virus
ubiquit
pathogen
share
number
epidemiolog
featur
respons
outbreak
occur
remark
season
pattern
season
variat
viral
activ
occur
temper
climat
tend
disappear
equatori
zone
phenomenon
incomplet
understood
may
involv
specif
viral
characterist
also
season
chang
live
condit
influenza
rsv
human
mpv
coronaviru
activ
peak
winter
month
caus
outbreak
fall
season
less
pronounc
picornavirida
exhibit
yearround
activ
peak
spring
spring
fall
human
rhinovirus
summer
fall
nonpoliomyelit
enterovirus
littl
known
epidemiolog
sinc
viru
respons
mild
infect
therefor
rare
identifi
common
respiratori
virus
typic
caus
infect
earli
childhood
influenza
c
usual
caus
mild
infect
lead
acquisit
protect
antibodi
capabl
prevent
recurr
influenza
b
consider
common
caus
diseas
greater
sever
notabl
highrisk
group
elderli
peopl
patient
chronic
respiratori
cardiovascular
condit
chronic
renal
failur
diabet
mellitu
immun
defici
estim
adult
children
experi
influenza
episod
everi
year
throughout
world
although
influenza
episod
mild
high
occurr
rate
result
huge
burden
diseas
sever
socioeconom
impact
influenza
virus
believ
seventh
caus
death
usa
influenza
b
infect
start
childhood
continu
occur
throughout
life
span
antigen
variat
affect
ha
lesser
extent
na
hamper
acquisit
protect
immun
two
mechan
antigen
variat
describ
antigen
drift
antigen
shift
antigen
drift
probabl
result
accumul
point
mutat
occur
continu
influenza
virus
new
variant
appear
annual
everi
year
new
variant
replac
preexist
one
immunolog
select
incomplet
recognis
immun
result
exposur
earlier
strain
antigen
shift
consider
rarer
event
occur
influenza
result
viru
complet
new
ha
na
result
influenza
pandem
due
absenc
protect
immun
new
viru
progress
acquisit
immun
new
strain
attenu
intens
epidem
follow
year
exact
genet
mechan
antigen
shift
incomplet
known
emerg
pandem
strain
predict
pandem
strain
origin
recombin
influenza
strain
circul
differ
anim
speci
includ
bird
pig
human
five
pandem
occur
twentieth
centuri
mexican
flu
pandem
due
new
influenza
viru
first
pandem
twentyfirst
centuri
rsv
piv
typic
infect
earli
childhood
rsv
lesser
extent
piv
also
undergo
antigen
chang
lead
recurr
throughout
life
span
recurr
may
sever
especi
patient
chronic
respiratori
condit
elderli
burden
rsvrelat
diseas
may
compar
influenza
data
avail
specif
epidemiolog
characterist
common
respiratori
virus
patient
hm
report
incid
rate
vari
wide
variabl
may
explain
dispar
type
patient
enrol
reason
screen
patient
respiratori
virus
importantli
diagnost
method
use
whatev
exact
incid
one
reason
assum
attack
rate
common
respiratori
virus
immunocompromis
patient
close
relat
preval
respiratori
virus
commun
serv
viral
reservoir
immunocompromis
patient
confirm
recent
studi
show
occurr
viral
respiratori
diseas
enrol
immunocompromis
patient
parallel
concomit
viral
activ
commun
accordingli
influenza
virus
rsv
virus
commonli
identifi
largest
cohort
hm
patient
account
onethird
viral
respiratori
event
piv
picornavirida
adenovirus
come
next
must
point
influenza
virus
account
much
higher
proport
viral
respiratori
event
studi
martino
et
al
conduct
set
major
influenza
outbreak
commun
adenoviru
epidemiolog
patient
hm
deserv
special
attent
similar
common
respiratori
virus
adenovirus
caus
primari
infect
childhood
usual
first
year
life
adenovirus
may
account
viral
respiratori
infect
children
also
caus
outbreak
close
semiclos
popul
young
adult
militari
distinct
featur
adenovirus
abil
caus
chronic
latent
infect
persist
lymphoepitheli
tissu
notabl
nasopharynx
epidemiolog
adenovirus
patient
hm
focu
specif
studi
nevertheless
exogen
contamin
respiratori
orofaec
rout
may
less
import
reactiv
latent
viru
thu
adenovir
infect
patient
hm
may
relat
chiefli
level
immunosuppress
perhap
unknown
viral
factor
drive
reactiv
rather
level
viral
activ
commun
epidemiolog
characterist
influenza
rsv
piv
particularli
well
known
perhap
part
infect
virus
consider
common
compar
due
virus
howev
avail
simpl
rapid
diagnost
tool
three
virus
probabl
play
great
role
sinc
picornavirida
coronavirida
newli
discov
human
mpv
mainli
diagnos
use
reversetranscriptas
polymerasechainreact
technolog
rtpcr
data
epidemiolog
still
limit
recent
studi
use
rtpcr
detect
respiratori
virus
patient
hm
reveal
high
incid
human
mpv
infect
similar
rsv
infect
near
futur
studi
use
molecular
biolog
tool
may
help
clarifi
epidemiolog
common
respiratori
virus
may
lead
radic
chang
current
concept
common
respiratori
viru
infect
studi
chiefli
patient
receiv
highdos
chemotherapi
haematopoiet
stem
cell
transplant
hsct
compar
immunocompet
patient
sever
distinct
featur
report
viral
shed
last
longer
progress
pneumonia
common
late
airflow
obstruct
report
hsct
recipi
respiratori
virus
respons
extrarespiratori
manifest
although
rare
immunocompet
host
manifest
might
common
patient
hm
common
respiratori
viral
infect
patient
hm
character
prolong
viral
shed
median
durat
week
found
studi
howev
viral
shed
may
last
month
case
addit
amount
viru
shed
per
day
may
greater
hm
patient
immunocompet
individu
similarli
find
immunocompromis
patient
children
shed
virus
longer
period
adult
prolong
highload
viral
shed
critic
import
sinc
may
enhanc
viral
dissemin
emerg
resist
strain
via
prolong
exposur
antivir
drug
state
common
respiratori
virus
long
underrecognis
patient
hm
first
report
common
respiratori
viru
infect
focus
influenza
rsv
studi
progress
pneumonia
occur
patient
infect
influenza
virus
infect
rsv
associ
mortal
rate
influenza
rsv
one
possibl
explan
strike
observ
may
surg
interest
respiratori
viral
infect
hm
patient
led
public
sever
case
surprisingli
studi
small
number
patient
high
rate
nosocomi
infect
recent
studi
larg
patient
cohort
led
better
character
influenzarel
pneumonia
patient
hm
onethird
patient
develop
lower
respiratori
tract
infect
lrti
although
less
common
previou
report
influenzarel
pneumonia
remain
sever
condit
mortal
rate
immunocompet
host
upper
respiratori
tract
infect
urti
almost
alway
present
often
preced
lrti
urti
consid
use
argument
support
diagnosi
respiratori
viral
infect
patient
hm
investig
pneumonia
howev
identif
common
respiratori
viru
exclud
associ
bacteri
fungal
infect
coinfect
frequent
occur
case
influenzarel
pneumonia
report
extrarespiratori
manifest
patient
hm
although
myocard
pericard
myositi
meningoenceph
syndrom
rey
syndrom
describ
immunocompet
patient
rsvrelat
pneumonia
believ
complic
rsv
infect
patient
hm
mortal
remain
high
rang
urti
common
clinic
manifest
clear
data
incid
concomit
bacteri
fungal
infect
avail
literatur
rsvrelat
pneumonia
patient
hm
often
ascrib
viral
infect
howev
bacteri
coinfect
present
mani
patient
larg
studi
rsv
infect
immunocompet
individu
bacteri
fungal
coinfect
may
common
patient
hm
must
care
sought
nonsustain
viraemia
may
accompani
rsv
infect
rsv
associ
cardiac
arrhythmia
neurolog
disord
two
case
report
howev
extrarespiratori
manifest
rsv
infect
describ
immunocompromis
patient
piv
infect
also
studi
patient
hm
piv
type
caus
report
case
studi
pivrel
pneumonia
compar
influenzarel
pneumonia
one
third
patient
affect
high
rate
concomit
urti
mortal
rate
coinfect
found
mani
patient
studi
nichol
et
al
howev
recent
studi
use
rtpcr
routin
respiratori
viru
detect
hsct
recipi
piv
found
respiratori
sampl
asymptomat
patient
wherea
influenza
rsv
human
mpv
detect
find
suggest
studi
use
convent
diagnost
method
may
overestim
true
sever
piv
patient
hm
report
suggest
role
occurr
neurolog
manifest
mening
enceph
syndrom
myocard
manifest
report
immunocompromis
patient
case
report
suggest
recent
discov
human
mpv
may
induc
sever
pneumonia
patient
hm
knowledg
two
retrospect
cohort
three
prospect
cohort
describ
human
mpv
infect
patient
hm
publish
small
number
patient
highli
variabl
result
pneumonia
patient
mortal
rate
preclud
definit
conclus
human
mpvrelat
pneumonia
patient
hm
although
debat
occurr
asymptomat
viral
shed
may
suggest
lesser
sever
human
mpvrelat
pneumonia
compar
influenza
rsv
two
case
enceph
human
mpv
detect
cerebrospin
fluid
immunocompet
paediatr
patient
publish
extrarespiratori
manifest
report
patient
hm
sinc
identif
picornavirida
coronavirida
reli
chiefli
molecular
biolog
tool
limit
data
avail
contribut
respiratori
viral
infect
patient
hm
epidemiolog
evid
support
associ
human
rhinoviru
lrti
immunocompet
children
elderli
peopl
despit
grow
evid
human
rhinoviru
abl
replic
lower
respiratori
tract
cell
vitro
vivo
whether
viru
caus
pneumonia
remain
debat
sever
report
patient
hm
link
human
rhinoviru
lrti
howev
retrospect
studi
small
patient
popul
high
rate
pulmonari
copathogen
identif
fail
demonstr
clear
role
human
rhinoviru
develop
pneumonia
nonpoliomyelit
enterovirus
chiefli
respons
urti
studi
small
number
patient
focus
virus
patient
hm
conclus
drawn
result
coronavirida
also
princip
respons
urti
may
occasion
caus
pneumonia
studi
evalu
role
coronavirida
patient
hm
two
case
report
publish
although
clear
common
respiratori
virus
respons
increas
rate
pneumonia
patient
hm
tabl
fig
exact
natur
caus
mechan
pneumonia
situat
remain
unknown
risk
factor
virusrel
pneumonia
found
consist
studi
lymphocytopenia
defin
use
varieti
cutoff
one
studi
found
lymphocytopenia
absolut
lymphocyt
count
less
cellsml
independ
associ
mortal
patient
influenzarel
pneumonia
higher
incid
greater
sever
virusrel
pneumonia
note
hsct
recipi
compar
patient
hm
find
may
reflect
deeper
lymphocyt
deplet
howev
studi
martino
et
al
pneumonia
rate
compar
patient
without
lymphocytopenia
possibl
higher
incid
greater
sever
virusrel
pneumonia
within
first
day
hsct
compar
infect
occur
later
may
reflect
deeper
lymphocyt
deplet
similar
mechan
may
underli
surpris
protect
effect
corticosteroid
therapi
studi
nichol
et
al
sinc
treatment
often
given
treat
graftversushost
diseas
gvhd
lymphoid
engraft
common
respiratori
virus
increas
mortal
patient
hm
mainli
caus
sever
pneumonia
may
also
contribut
longterm
declin
pulmonari
function
rsv
piv
influenza
infect
link
late
airflow
obstruct
hsct
recipi
studi
focus
specif
role
respiratori
virus
late
airflow
obstruct
piv
lrti
strongest
risk
factor
follow
piv
urti
pneumonia
caus
rsv
borderlinesignific
risk
factor
exact
caus
mechan
remain
unknown
inflamm
result
prolong
viral
persist
pneumoniainduc
postacutephas
inflamm
suggest
possibl
factor
distinct
featur
adenovirus
hm
patient
may
either
acquir
via
exogen
respiratori
orofaec
contamin
aris
via
reactiv
latent
virus
adenovirus
caus
wide
spectrum
clinic
manifest
rang
benign
conjunct
rapidli
fatal
dissemin
diseas
patient
hm
risk
sever
adenovir
diseas
seem
relat
level
immunosuppress
adenovir
diseas
report
hsct
recipi
within
first
day
transplant
higher
rate
may
occur
paediatr
patient
compar
adult
vivo
ex
vivo
graft
tcell
deplet
lymphocytopenia
gvhd
viral
shed
one
site
adenoviru
viraemia
report
risk
factor
sever
adenovir
diseas
adenoviru
viraemia
consist
preced
viral
shed
one
site
studi
chakrabarti
et
al
risk
factor
critic
import
sinc
guid
preemptiv
antivir
therapi
adenovir
diseas
chiefli
report
myeloabl
hsct
recipi
also
describ
nonmyeloabl
hsct
recipi
autolog
transplant
recipi
patient
chronic
lymphocyt
leukaemia
treat
fludarabin
combin
monoclon
antibodi
allogen
transplant
recipi
frequent
manifest
adenovir
infect
gastrointestin
diseas
haemorrhag
cystiti
although
haemorrhag
cystiti
benign
localis
event
associ
high
morbid
must
point
patient
febril
haematuria
adenoviru
urinari
excret
onset
acut
renal
failur
flank
pain
may
reveal
adenoviru
nephriti
gastrointestin
manifest
includ
gastroenter
coliti
often
manifest
febril
haemorrhag
diarrhoea
sever
manifest
adenovir
infect
hepat
enceph
pneumonia
adenovirusrel
pneumonia
occur
patient
adenoviru
infect
studi
la
rosa
et
al
pneumonia
isol
patient
manifest
dissemin
diseas
patient
bacteri
fungal
coinfect
found
patient
keep
studi
mortal
rate
overal
patient
isol
pneumonia
patient
dissemin
diseas
chapter
dr
sandherr
dedic
antivir
therapi
book
regard
common
virus
briefli
describ
avail
treatment
influenza
rsv
two
class
antivir
drug
avail
treatment
influenza
ion
channel
inhibitor
neuraminidas
inhibitor
ion
channel
inhibitor
amantadin
rimantadin
act
inhibit
protein
need
viral
rna
releas
within
host
cell
activ
influenza
strain
clinic
effect
limit
significantli
differ
placebo
hamper
worldwid
emerg
resist
influenza
strain
neuraminidas
inhibitor
tabl
oral
oseltamivir
inhal
zanamivir
sialic
acid
analogu
competit
inhibit
influenza
neuraminidas
randomis
control
trial
show
moder
decreas
symptom
intens
durat
drug
neuraminidas
inhibitor
may
also
limit
bacteri
superinfect
lung
earli
administr
drug
seem
mandatori
obtain
clinic
benefit
recent
cohort
studi
suggest
diminut
mortal
neuraminidas
inhibitor
result
must
interpret
caution
especi
given
studi
design
grow
concern
emerg
oseltamivirresist
influenza
strain
phenomenon
surpris
given
high
mutat
rate
influenza
genom
lead
clinician
reconsid
indic
neuraminidas
inhibitor
use
monotherapi
treat
influenza
randomis
control
trial
evalu
efficaci
neuraminidas
inhibitor
patient
hm
appar
lower
mortal
descript
cohort
studi
compar
histor
studi
must
interpret
caution
mani
patient
cohort
bacteri
fungal
coinfect
whose
specif
treatment
probabl
contribut
decreas
mortal
furthermor
decis
treat
patient
left
clinician
discret
may
introduc
bia
toward
select
patient
greater
diseas
sever
given
absenc
strong
evid
support
benefici
effect
neuraminidas
inhibitor
therapi
rapid
emerg
resist
strain
believ
neuraminidas
inhibitor
therapi
recommend
hm
patient
influenza
randomis
control
trial
need
determin
efficaci
safeti
ecolog
impact
neuraminidas
inhibitor
patient
ribavirin
avail
antivir
drug
paramyxovirida
infect
tabl
efficaci
aerosol
ribavirin
variabl
uncontrol
cohort
patient
rsvrelat
pneumonia
result
must
interpret
caution
earli
ribavirin
therapi
introduc
onset
respiratori
failur
seem
associ
lower
mortal
studi
whimbey
et
al
observ
led
author
evalu
preemptiv
ribavirin
therapi
characteris
ribavirin
treatment
rsv
urti
prevent
progress
pneumonia
studi
boeckh
et
al
randomis
control
trial
evalu
preemptiv
ribavirin
therapi
patient
rsv
infect
unfortun
trial
enrol
suffici
number
patient
produc
conclus
intraven
ribavirin
also
evalu
found
unhelp
combin
ribavirin
intraven
immunoglobulin
rsvspecif
immunoglobulin
produc
variabl
level
efficaci
cohort
studi
palivizumab
rsvspecif
monoclon
antibodi
evalu
small
cohort
vitro
ribavirin
exhibit
mild
antivir
activ
piv
clear
efficaci
aerosol
ribavirin
found
small
uncontrol
cohort
patient
hm
earli
initi
ribavirin
therapi
propos
enhanc
efficaci
studi
evalu
intraven
immunoglobulin
rsvspecif
immunoglobulin
contain
high
titr
pivspecif
immunoglobulin
vitro
studi
suggest
ribavirin
may
interest
treat
human
mpvrelat
pneumonia
drug
evalu
patient
hm
date
strong
evid
support
use
ribavirin
either
alon
combin
immunoglobulin
treat
paramyxoviridaerel
pneumonia
patient
hm
control
randomis
studi
evalu
treatment
adenovir
diseas
patient
hm
ribavirin
cidofovir
suggest
treatment
adenovir
infect
uncontrol
cohort
studi
avail
support
use
intraven
ribavirin
therapi
fail
demonstr
benefit
avail
studi
cidofovir
therapi
tabl
seem
result
better
outcom
small
uncontrol
seri
ganciclovir
antiretrovir
drug
zalcitabin
alovudin
stavudin
exhibit
vitro
activ
adenovirus
specif
evalu
clinic
set
consid
lack
specif
antivir
drug
decreas
level
immunosuppress
seem
ration
treatment
approach
tcell
therapi
also
report
small
seri
earli
cidofovir
treatment
seem
associ
better
outcom
weekli
pcr
screen
adenoviru
viraemia
suggest
guid
preemptiv
cidofovir
therapi
exact
threshold
preemptiv
cidofovir
therapi
initi
unknown
randomis
control
trial
need
better
defin
optim
viraemia
threshold
antivir
therapi
evalu
benefit
treatment
greater
sever
common
respiratori
viral
infect
hm
patient
lack
clearli
proven
effect
antivir
drug
emphasis
critic
import
prevent
strategi
occurr
common
respiratori
viru
infect
patient
hm
close
relat
viral
activ
commun
howev
nosocomi
outbreak
describ
haematolog
ward
often
within
day
outbreak
commun
prevent
nosocomi
transmiss
common
respiratori
virus
requir
multifacet
approach
tabl
target
mode
transmiss
also
sourc
virus
nosocomi
outbreak
believ
origin
infect
patient
infect
healthcar
worker
infect
control
measur
includ
screen
symptomat
patient
common
respiratori
virus
earli
isol
infect
patient
screen
healthcar
worker
visitor
respiratori
symptom
avoid
contact
symptomat
individu
patient
haematolog
ward
allow
children
visit
patient
children
highli
prone
common
respiratori
viru
infect
may
exhibit
viral
shed
long
symptom
resolut
continu
reinforc
standard
hygien
measur
especi
hand
hygien
contact
patient
also
strongli
recommend
awar
use
measur
therefor
adher
measur
low
enhanc
educ
program
common
respiratori
virus
transmit
droplet
direct
contact
infect
secret
nasal
mucosa
conjunctiva
indirect
transmiss
via
contamin
fomit
devic
also
possibl
sinc
virus
may
surviv
sever
hour
surfac
consequ
contact
isol
infect
patient
combin
droplet
precaut
mandatori
gown
glove
mask
eye
protect
must
worn
contact
infect
patient
airborn
transmiss
influenza
suspect
yet
proven
two
recent
studi
suggest
surgic
mask
may
effect
prevent
influenza
transmiss
mask
greater
filtrat
capac
infect
control
measur
evalu
randomis
control
trial
beforeandaft
studi
suggest
may
help
prevent
transmiss
common
respiratori
virus
must
point
asymptomat
viral
shed
present
limit
effect
infect
control
measur
optim
durat
isol
unknown
whether
isol
prolong
asymptomat
patient
persist
lowtitr
viral
shed
detect
molecular
method
remain
unclear
sinc
adenoviru
acquisit
known
result
also
endogen
reactiv
adenovir
infect
may
chiefli
relat
level
immunosuppress
therefor
may
effect
prevent
standard
infect
control
measur
date
influenza
common
respiratori
viru
vaccin
avail
immunis
remain
cornerston
influenza
prevent
immunogen
inactiv
influenza
vaccin
lower
patient
hm
compar
immunocompet
control
second
dose
influenza
vaccin
propos
enhanc
immunogen
strategi
benefici
openlabel
randomis
studi
time
influenza
immunis
may
import
immunogen
may
improv
give
vaccin
least
month
hsct
least
day
intens
chemotherapi
efficaci
influenza
immunis
evalu
randomis
control
trial
howev
retrospect
cohort
studi
suggest
benefit
influenza
immunis
hsct
recipi
influenza
immunis
appear
safe
patient
hm
lifelong
season
administr
influenza
vaccin
therefor
recommend
highrisk
patient
importantli
famili
contact
immunis
also
prevent
transmiss
within
household
critic
import
issu
healthcar
worker
immunis
known
prevent
nosocomi
acquisit
viru
pharmacolog
intervent
propos
prevent
common
respiratori
viru
infect
intraven
immunoglobulin
palivizumab
suggest
rsv
infect
prevent
evalu
patient
hm
prophylact
postexposur
oseltamivir
therapi
current
recommend
patient
hm
prevent
measur
evalu
randomis
control
trial
seem
safe
base
recent
retrospect
studi
hsct
recipi
consid
lack
proven
benefit
oseltamivir
therapi
grow
concern
emerg
oseltamivirresist
influenza
strain
oseltamivir
therapi
care
evalu
suggest
use
larg
scale
anoth
way
prevent
morbid
mortal
relat
common
respiratori
virus
patient
hm
limit
risk
progress
pneumonia
preemptiv
treatment
viral
urti
discuss
given
sever
common
respiratori
viru
pneumonia
patient
hm
appear
logic
prudent
postpon
hsct
patient
document
viral
infect
retrospect
cohort
studi
suggest
measur
might
prevent
rsvrelat
pneumonia
patient
undergo
hsct
unclear
whether
measur
might
appli
type
hsct
intens
chemotherapi
cours
respiratori
virus
common
respiratori
virus
recognis
true
opportunist
respiratori
pathogen
patient
hm
patient
constitut
common
caus
potenti
sever
pneumonia
howev
area
uncertainti
remain
indic
need
investig
epidemiolog
common
respiratori
viru
infect
patient
hm
extens
studi
larg
epidemiolog
studi
common
respiratori
viru
infect
patient
hm
base
molecular
biolog
tool
may
lead
radic
chang
knowledg
although
clear
common
respiratori
virus
respons
increas
pneumonia
rate
patient
hm
exact
natur
caus
mechan
pneumonia
case
remain
unknown
studi
warrant
investig
role
virus
develop
lrti
viru
might
directli
injur
alveolar
epithelium
promot
lung
superinfect
caus
bronchial
epithelium
damag
studi
would
also
help
determin
potenti
benefit
preemptiv
cur
antivir
therapi
final
randomis
control
studi
antivir
therapi
patient
hm
urgent
need
